241 related articles for article (PubMed ID: 21805051)
1. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
[TBL] [Abstract][Full Text] [Related]
2. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
4. IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide.
Natsume A; Ishii D; Wakabayashi T; Tsuno T; Hatano H; Mizuno M; Yoshida J
Cancer Res; 2005 Sep; 65(17):7573-9. PubMed ID: 16140920
[TBL] [Abstract][Full Text] [Related]
5. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Park JA; Joe YA; Kim TG; Hong YK
Oncol Rep; 2006 Dec; 16(6):1253-60. PubMed ID: 17089046
[TBL] [Abstract][Full Text] [Related]
7. A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation.
Natsume A; Wakabayashi T; Ishii D; Maruta H; Fujii M; Shimato S; Ito M; Yoshida J
Cancer Chemother Pharmacol; 2008 Apr; 61(4):653-9. PubMed ID: 17564708
[TBL] [Abstract][Full Text] [Related]
8. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
9. Combined temozolomide and sunitinib treatment leads to better tumour control but increased vascular resistance in O6-methylguanine methyltransferase-methylated gliomas.
Czabanka M; Bruenner J; Parmaksiz G; Broggini T; Topalovic M; Bayerl SH; Auf G; Kremenetskaia I; Nieminen M; Jabouille A; Mueller S; Harms U; Harms C; Koch A; Heppner FL; Vajkoczy P
Eur J Cancer; 2013 Jun; 49(9):2243-52. PubMed ID: 23499430
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy.
Lin CJ; Lee CC; Shih YL; Lin TY; Wang SH; Lin YF; Shih CM
Free Radic Biol Med; 2012 Jan; 52(2):377-91. PubMed ID: 22094224
[TBL] [Abstract][Full Text] [Related]
11. Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level.
Gong A; Ge N; Yao W; Lu L; Liang H
Cancer Chemother Pharmacol; 2014 Sep; 74(3):531-8. PubMed ID: 25047724
[TBL] [Abstract][Full Text] [Related]
12. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
[TBL] [Abstract][Full Text] [Related]
13. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas.
Pyrko P; Schönthal AH; Hofman FM; Chen TC; Lee AS
Cancer Res; 2007 Oct; 67(20):9809-16. PubMed ID: 17942911
[TBL] [Abstract][Full Text] [Related]
14. Local delivery of slow-releasing temozolomide microspheres inhibits intracranial xenograft glioma growth.
Dong J; Zhou G; Tang D; Chen Y; Cui B; Dai X; Zhang J; Lan Q; Huang Q
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2079-84. PubMed ID: 22825126
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma.
Patel R; Shervington L; Lea R; Shervington A
Brain Res; 2008 Jan; 1188():173-81. PubMed ID: 18021753
[TBL] [Abstract][Full Text] [Related]
16. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas.
Soritau O; Tomuleasa C; Aldea M; Petrushev B; Susman S; Gheban D; Ioani H; Cosis A; Brie I; Irimie A; Kacso G; Florian IS
J BUON; 2011; 16(2):282-9. PubMed ID: 21766499
[TBL] [Abstract][Full Text] [Related]
17. Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Pan SJ; Wu YB; Cai S; Pan YX; Liu W; Bian LG; Sun B; Sun QF
Biochem Biophys Res Commun; 2015 Mar; 458(3):476-482. PubMed ID: 25680464
[TBL] [Abstract][Full Text] [Related]
18. Combination of temozolomide and Taxol exerts a synergistic inhibitory effect on Taxol‑resistant glioma cells via inhibition of glucose metabolism.
Guan DG; Chen HM; Liao SF; Zhao TZ
Mol Med Rep; 2015 Nov; 12(5):7705-11. PubMed ID: 26459853
[TBL] [Abstract][Full Text] [Related]
19. Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest.
Wang P; Ye JA; Hou CX; Zhou D; Zhan SQ
Oncol Rep; 2016 Nov; 36(5):2544-2552. PubMed ID: 27633132
[TBL] [Abstract][Full Text] [Related]
20. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
